While in many instances "no news is good news" maybe true, in the case of MSB it isn't.
We can assume Oaktree's risk assssment in regard to the MSB loans is flashing red.
And nothing about the progress on a new aGVHD trial, the type A meeting with the FDA, or anything else for that matter.
The only news likely IMO is a trading halt followed by a suspension from trading. The only other possibility is a cap raise at whatever Bell Potter thinks the market can stand. When is the next quarterly report due?
Ann: Mesoblast Type A Meeting with FDA, page-383
-
- There are more pages in this discussion • 192 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |